Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris.

Murrell, D F; Patsatsi, A; Stavropoulos, P; Baum, S; Zeeli, T; Kern, J S; Sinclair, R; Neale, A; Arora, P; Sugerman, P B; Shi, G; Werth, V P; Caux, F; Joly, P

Murrell, D F; Patsatsi, A; Stavropoulos, P; Baum, S; Zeeli, T; Kern, J S; Sinclair, R; Neale, A; Arora, P; Sugerman, P B; Shi, G; Werth, V P; Caux, F; Joly, P.

Afiliação

Murrell DF; Department of Dermatology, St George Hospital, University of New South Wales Faculty of Medicine, Sydney, Australia.
Patsatsi A; 2nd Dermatology Department, Aristotle University Faculty of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
Stavropoulos P; 1st Department of Dermatology, National and Kapodistrian University, School of Medicine, Athens, Greece.
Baum S; Department of Dermatology, Sheba Medical Center, Ramat Gan, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Zeeli T; Department of Dermatology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Kern JS; Dermatology Department, The Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, Australia.
Sinclair R; University of Melbourne and Sinclair Dermatology, Victoria, Australia.
Neale A; Principia Biopharma Inc, a Sanofi Company, South San Francisco, California, United States.
Arora P; Principia Biopharma Inc, a Sanofi Company, South San Francisco, California, United States.
Sugerman PB; Global Medical Affairs, Sanofi Genzyme, Cambridge, Massachusetts, United States.
Shi G; Biostatistics, Sanofi US Services Inc., Bridgewater, New Jersey, United States.
Werth VP; University of Pennsylvania Perelman School of Medicine and Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, United States.
Caux F; Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, AP-, HP, Bobigny, France.
Joly P; Department of Dermatology, Rouen University Hospital, Centre de Référence des Maladies Bulleuses Autoimmunes, and INSERM U1234, Normandie University, Rouen, France.